Listed by the USPTO as CRAIGO, BAHAR ALAWI
Tech Center 1700 • Art Units: 1623 1673 1681 1699 1734 1759
This examiner grants 47% of resolved cases
CRAIGO, BAHAR ALAWI examines in USPTO Technology Center 1700 and art unit 1623. The record includes 799 resolved cases, a 47.3% allowance rate, and a 27.2% interview lift. The median time to allowance is 1230 days. The lower allowance figure and positive interview association suggest that interviews may be particularly relevant to prosecution planning, while not replacing claim-focused written practice.
The leading companies are Boehringer Ingelheim International GmbH, The Regents of the University of California, and Dana-Farber Cancer Institute Inc. The leading firms are Knowles Intellectual Property Strategies, LLC, Muncy, Geissler, Olds & Lowe, P.C., and QUARLES & BRADY LLP. The profile is useful for identifying biomedical applicants and counsel with recurring matters before this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18461850 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | Final Rejection | Boehringer Ingelheim International GmbH |
| 18578118 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | Non-Final OA | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 18214162 | WATER-SOLUBLE DIETARY FIBER, USE THEREOF IN PREPARATION OF MEDICAMENT THAT PROMOTES METABOLISM OF ELLAGIC ACID INTO UROLITHIN A, AND PHARMACEUTICAL COMPOSITION | Final Rejection | ZHEJIANG UNIVERSITY |
| 17139665 | COMPOSITIONS AND METHODS TO ACCELERATE RESOLUTION OF ACUTE LUNG INFLAMMATION | Non-Final OA | The Johns Hopkins University |
| 18920285 | GLYCOSYLATION INHIBITORS AS THERAPEUTICS FOR STROKE | Non-Final OA | The Regents of the University of California |
| 18323122 | NOVEL APPLICATIONS OF HYALURONIC ACID FOR TREATMENT OF PAIN AND PRURITIS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18685028 | NOVEL USE OF AT LEAST A HUMAN MILK OLIGOSACCHARIDE | Non-Final OA | DSM IP ASSETS B.V. |
| 17738286 | COMPOSITION FOR MAINTAINING LACTOBACILLUS DOMINANCE | Final Rejection | Kimberly-Clark Worldwide, Inc. |
| 18026057 | AUTOPHAGY ACTIVATOR | Final Rejection | Resonac Corporation |
| 18696840 | NICOTINAMIDE RIBOSIDE TRIOLEATES CHLORIDE, COMPOSITIONS CONTAINING THIS COMPOUND, AND METHODS OF MAKING AND USING THIS COMPOUND | Non-Final OA | CORNELL UNIVERSITY |
| 17348354 | GUAR HYDROXYPROPYLTRIMETHYLAMMONIUM CHLORIDE AND USES THEREOF IN HAIR TREATMENT COMPOSITIONS | Non-Final OA | SPECIALTY OPERATIONS FRANCE |
| 18270069 | A BIOMATERIAL WITH A HIGH GLYCOSAMINOGLYCAN/HYDROXYPROLINE RATIO, COMPOSITION, METHODS AND APPLICATIONS | Non-Final OA | THE UNIVERSITY OF HONG KONG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy47.3% of resolved applications examined by Bahar Alawi Craigo were allowed (799 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +27.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Bahar Alawi Craigo took 1,230 days on average from filing to allowance.
Bahar Alawi Craigo examines applications in Art Unit 1623 in Tech Center 1700 (Chemistry & Materials).
